About Cookies on This Site

This website uses cookies to improve and customize your experience on our website. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our Cookie Policy.

Did you know? NUPLAZID capsules can be opened and sprinkled. Learn how.

They stayed connected and faced his Parkinson’s disease (PD) together. Don’t let them fight PD psychosis alone.

The time for NUPLAZID is now.
For your patients with PD psychosis: The only FDA-approved therapy for the treatment of hallucinations and delusions associated with PD psychosis1,2

Download the treatment form
Homepage hero background image of actor portrayal: woman placing hand on arm of loved one while looking at him

Approximately 50% of patients with PD may develop hallucinations and/or delusions over the course of their disease.3*

*As determined by a prospective, longitudinal, cohort study, which followed community-based patients with PD (N=230) in Norway for 12 years to determine PDP prevalence as assessed by UPDRS ≥2 or antipsychotic use for PDP.

NUPLAZID significantly reduced the frequency and/or severity of hallucinations and delusions associated with PD psychosis at Week 6 vs placebo (Primary Endpoint).1†

Primary efficacy was evaluated based on the change from baseline to Week 6 in SAPS-PD total score (n=95 NUPLAZID; n=90 placebo).

NUPLAZID has a demonstrated safety profile in elderly patients with PD psychosis1

Illustration showing NUPLAZID® safety profile in elderly patients with PD psychosis
Illustration showing NUPLAZID® safety profile in elderly patients with PD psychosis
  • In the 6-week placebo-controlled studies, 80% of patients on NUPLAZID were aged 65 years or older (maximum age on NUPLAZID vs placebo was 85 and 90, respectively).4
  • No differences in safety were reported based on age, gender, or Mini-Mental State Examination (MMSE) score

    • 27% of patients had MMSE score of 21-24

  • The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%)

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.

Warnings and Precautions: QT Interval Prolongation

  • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.

  • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Acadia Connect logo for patient, caregiver, and healthcare professional support website

Acadia Connect makes it easy to get patients started on NUPLAZID and provides the support they deserve.

See how we can help
Holding hands to provide comfort represents Acadia Connect support for patients

IMPORTANT SAFETY INFORMATION and INDICATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation

    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.

    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

  • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

  • Drug Interactions:

    • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.

    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full Prescribing Information, including Boxed WARNING.

References:
  1. Acadia Pharmaceuticals Inc. NUPLAZID® [package insert]. San Diego, CA; 2020.
  2. US Food and Drug Administration. FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm498442.htm. April 29, 2016. Accessed June 17, 2020.
  3. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population based study of psychosis in Parkinson disease. *Arch Neurol*. 2010;67(8):996-1001.
  4. Acadia Pharmaceuticals Inc. NUPLAZID Advisory Committee Briefing Document. San Diego, CA: Sponsor Background Information for a Meeting of the Psychopharmacologic Drugs Advisory Committee; March 29, 2016. https://www.fda.gov/media/96755/download. Accessed June 17, 2020.